BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24985972)

  • 21. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
    Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
    BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular alterations in prostate cancer and association with MRI features.
    Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN stability.
    Li X; Li Z; Li N; Qi J; Fan K; Yin P; Zhao C; Liu Y; Yao W; Cai X; Wang L; Zha X
    Int J Mol Med; 2013 Aug; 32(2):439-47. PubMed ID: 23754155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
    Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
    Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
    Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population.
    Al Bashir S; Alorjani MS; Kheirallah K; Al Hamad M; Haddad HK; Al-Dwairy A; Bani-Fawwaz BA; Aldaoud N; Halalsheh O; Amawi S; Matalka II
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256434
    [No Abstract]   [Full Text] [Related]  

  • 28. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.
    Erdmann K; Kaulke K; Thomae C; Huebner D; Sergon M; Froehner M; Wirth MP; Fuessel S
    BMC Cancer; 2014 Feb; 14():82. PubMed ID: 24517338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer.
    Altintas DM; Allioli N; Decaussin M; de Bernard S; Ruffion A; Samarut J; Vlaeminck-Guillem V
    PLoS One; 2013; 8(6):e66278. PubMed ID: 23840433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
    Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
    PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
    Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
    Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The genomic complexity of primary human prostate cancer.
    Berger MF; Lawrence MS; Demichelis F; Drier Y; Cibulskis K; Sivachenko AY; Sboner A; Esgueva R; Pflueger D; Sougnez C; Onofrio R; Carter SL; Park K; Habegger L; Ambrogio L; Fennell T; Parkin M; Saksena G; Voet D; Ramos AH; Pugh TJ; Wilkinson J; Fisher S; Winckler W; Mahan S; Ardlie K; Baldwin J; Simons JW; Kitabayashi N; MacDonald TY; Kantoff PW; Chin L; Gabriel SB; Gerstein MB; Golub TR; Meyerson M; Tewari A; Lander ES; Getz G; Rubin MA; Garraway LA
    Nature; 2011 Feb; 470(7333):214-20. PubMed ID: 21307934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional landscape of PTEN loss in primary prostate cancer.
    Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
    BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.
    Bowen C; Ostrowski MC; Leone G; Gelmann EP
    Cancer Res; 2019 Aug; 79(16):4124-4134. PubMed ID: 31213464
    [No Abstract]   [Full Text] [Related]  

  • 37. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
    Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
    Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.